Literature DB >> 27535996

Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease.

Eli L Diamond1, Omar Abdel-Wahab2,3, Benjamin H Durham3,4, Ahmet Dogan4, Neval Ozkaya4, Lynn Brody5, Maria Arcila4, Christian Bowers6, Mark Fluchel7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27535996      PMCID： PMC5054701          DOI： 10.1182/blood-2016-06-725143

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  23 in total

1.  Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma.

Authors:  Lorraine Tracey; Raquel Villuendas; Pablo Ortiz; Ana Dopazo; Inmaculada Spiteri; Luis Lombardia; Jose L Rodríguez-Peralto; Jesús Fernández-Herrera; Almudena Hernández; Javier Fraga; Orlando Dominguez; Javier Herrero; Miguel A Alonso; Joaquin Dopazo; Miguel A Piris
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease.

Authors:  Fleur Cohen-Aubart; Philippe Maksud; David Saadoun; Aurélie Drier; Frédéric Charlotte; Philippe Cluzel; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2016-02-04       Impact factor: 22.113

3.  Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Authors:  Jean-François Emile; Eli L Diamond; Zofia Hélias-Rodzewicz; Fleur Cohen-Aubart; Frédéric Charlotte; David M Hyman; Eunhee Kim; Raajit Rampal; Minal Patel; Chezi Ganzel; Shlomzion Aumann; Gladwys Faucher; Catherine Le Gall; Karen Leroy; Magali Colombat; Jean-Emmanuel Kahn; Salim Trad; Philippe Nizard; Jean Donadieu; Valérie Taly; Zahir Amoura; Omar Abdel-Wahab; Julien Haroche
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

4.  Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein.

Authors:  Audrey Courcoul; Emmanuelle Vignot; Roland Chapurlat
Journal:  Joint Bone Spine       Date:  2013-08-13       Impact factor: 4.929

5.  Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs.

Authors:  T A Tran; D Pariente; J C Lecron; A Delwail; Y Taoufik; U Meinzer
Journal:  Arthritis Rheum       Date:  2011-12

6.  Erdheim-Chester disease with cardiac involvement successfully treated with anakinra.

Authors:  Ammar M Killu; Jackson J Liang; Allan S Jaffe
Journal:  Int J Cardiol       Date:  2013-05-06       Impact factor: 4.164

7.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

8.  Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra.

Authors:  Olivier Aubert; Achille Aouba; Soizic Deshayes; Sophie Georgin-Lavialle; Philippe Rieu; Olivier Hermine
Journal:  Joint Bone Spine       Date:  2012-09-19       Impact factor: 4.929

9.  Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis.

Authors:  Antonella Stoppacciaro; Marina Ferrarini; Chiara Salmaggi; Cristina Colarossi; Luisa Praderio; Moreno Tresoldi; Angelo A Beretta; Maria Grazia Sabbadini
Journal:  Arthritis Rheum       Date:  2006-12

10.  Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial.

Authors:  Adel Helmy; Mathew R Guilfoyle; Keri L H Carpenter; John D Pickard; David K Menon; Peter J Hutchinson
Journal:  J Cereb Blood Flow Metab       Date:  2014-02-26       Impact factor: 6.200
View more
  7 in total

1.  Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Authors:  Filip Janku; Eli L Diamond; Aaron M Goodman; Vaijayanthi Kandadai Raghavan; Tamara G Barnes; Shumei Kato; Omar Abdel-Wahab; Benjamin H Durham; Funda Meric-Bernstam; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

Review 2.  The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.

Authors:  Neval Ozkaya; Marc K Rosenblum; Benjamin H Durham; Janine D Pichardo; Omar Abdel-Wahab; Meera R Hameed; Klaus J Busam; William D Travis; Eli L Diamond; Ahmet Dogan
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

3.  Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Authors:  Fréderic Franconieri; Samuel Deshayes; Hubert de Boysson; Salim Trad; Nicolas Martin Silva; Benjamin Terrier; Boris Bienvenu; Françoise Galateau-Sallé; Jean-François Emile; Alison C Johnson; Achille Aouba
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

4.  Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease.

Authors:  Alessandro Tomelleri; Giulio Cavalli; Giacomo De Luca; Corrado Campochiaro; Teresa D'Aliberti; Moreno Tresoldi; Lorenzo Dagna
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561

5.  BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.

Authors:  J Picarsic; T Pysher; H Zhou; M Fluchel; T Pettit; M Whitehead; L F Surrey; B Harding; G Goldstein; Y Fellig; M Weintraub; B C Mobley; P M Sharples; M L Sulis; E L Diamond; R Jaffe; K Shekdar; M Santi
Journal:  Acta Neuropathol Commun       Date:  2019-11-04       Impact factor: 7.801

6.  Erdheim-Chester disease: First pediatric case report in Colombia

Authors:  Luis Carlos Salazar; Luz Ángela Moreno; Lina Eugenia Jaramillo; Edgar Vladimir Cabrera
Journal:  Biomedica       Date:  2021-12-15       Impact factor: 0.935

Review 7.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.